Israel Hyperlipidemia Drugs Market By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region, Competition, Forecast, and Opportunities, 2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIsrael Hyperlipidemia Drugs Market By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region, Competition, Forecast, and Opportunities, 2028
According to the Israel Medical Association Journal (IMAJ), hyperlipidemia is a major risk factor for coronary heart disease. Therefore, reducing low density lipoprotein-cholesterol can significantly reduce the risk of heart stroke.
Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by prominent levels of fats in the bloodstream.
Development of New and Improved Drugs
Download Free Sample ReportRecent Developments
- In December 2021, Novartis AG announced the U.S. Food andDrug Administration (FDA) approval of Leqvio (inclisiran). It lowerslow-density lipoprotein cholesterol with two doses annually, following a firstdose and one after three months, and is the first and only small interferingRNA (siRNA) therapy to do so. Leqvio increases the liver's natural capacity tosuppress the production of a protein that contributes to elevated bloodcholesterol levels, which lowers LDL-C levels in the bloodstream.
- Many clinical trials have been conducted by the marketplayers on the study of statin treatment for dyslipidemia.
- For instance, in November 2021, Pfizer Ltd announced toplineresults from the Phase 2b study of vupanorsen (PF-07285557), an experimentalantisense treatment being researched for indications in cardiovascular (CV)risk reduction and severe hypertriglyceridemia (SHTG), had topline data fromthe Phase 2b study released by Pfizer. According to the study, vupanorsensignificantly reduced non-HDL-C, triglycerides, and other lipoproteins linkedto cardiovascular disease.
- Additionally, in September 2022, the University ofPennsylvania started a clinical trial to evaluate the efficiency of statinsbased on non-visit and visit-based interventions for their optimized referralto patients affected by hyperlipidemia. Such studies which focus on theutilization of statins for the lipid disorders are expected to add to thegrowth of the market segment over the forecast period.
Increasing Prevalence of Hyperlipidemia
According to
According to a report by the Israel’s Ministry of Health, the prevalence of obesity among Israeli adults increased from 14% in 2003 to 26% in 2015 and it has been increased by 62 percent of men and 55% of women.
Furthermore, the growing awareness and support provided by the Israel government includes healthcare facilities and infrastructure. In Israel, approximately 25,000 hospitalizations occur because of myocardial infarction each year; 43,000 patients have coronary angiograms annually, and 23,000 patients undergo percutaneous coronary interventions, mostly in the same setting as diagnostic procedures, but approximately 50% occur during hospitalization because of acute coronary syndrome (ACS). These factors are expected to participate in the growth of Israel hyperlipidemia drugs market.
Market Segmentation
Israel hyperlipidemia drugs market is segmented
Market Players
Pfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, GlaxoSmithKline Israel Ltd., Israel B. Abbott., Takeda Israel Inc., Teva Israel Ltd., and Servier Israel Inc.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2022 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume Units, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends |
| Segments covered | Drug Class Type Region Company |
| Regional scope | The Mediterranean Coastal Plain, The Central Hills, The Jordan Rift Valley, and The Negev Desert |
| Key companies profiled | Pfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, GlaxoSmithKline Israel Ltd., Israel B. Abbott., Takeda Israel Inc., Teva Israel Ltd., and Servier Israel Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy